Company profile

BeBetter Med

China clinical-stage biopharma -- oncology, autoimmune, metabolic disease

688759 · SSE STAR Market · China

Public Market Listing

688759SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for BeBetter Med are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
BEBT-209
Phase 3
CDK4 (selective)Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
BEBT-109
Phase 2
EGFRSmall molecule
Non-Small Cell Lung Cancer
BEBT-701
Phase 2
Angiotensinogen (AGT) / PCSK9 (dual)Biologic — subtype unspecified
Hypertension
BEBT-908No recent activity
Phase 1
PI3K and HDAC (dual inhibition)Small molecule
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.